[1] SU Y Y，DU J T，XING M. Recent developments in anti-AIDS drugs[J] . Her Med(医药导报)，2003，22(12)： 854-855. [2] PENG S X. Progress in Medicinal Chemistry(药物化学进展)[M] . Vol 3. Beijing： Chemical Industry Press，2004： 1-23. [3] GITTI R K，LEE B M，WALKER J，et al. Structure of the amino-terminal core domain of the HIV-1 capsid protein[J] . Science，1996，273(5272)： 231-235. [4] VON SCHWEDLER U K，STEMMLER T L，KLISHKO V Y，et al. Proteolytic refolding of the HIV-1 capsid protein amino-terminus facilitates viral core assembly[J] .EMBO J，1998，17(6)： 1555-1568. [5] GROSS I，HOHENBERG H，HUCKHAGEL C，et al. N-Terminal extension of human immunodeficiency virus capsid protein converts the in vitro assembly phenotype from tubular to spherical particles[J] . J Virol，1998，72(6)： 4798-4810. [6] FREED E O. HIV-1 gag proteins： diverse functions in the virus life cycle[J] .Virology，1998，251(1)： 1-15. [7] CIMARELLI A，DARLIX J L. Assembling the human immunodeficiency virus type 1[J] .Cell Mol Life Sci，2002，59(7)： 1166-1184. [8] TURNER B G，SUMMERS M F. Structural biology of HIV[J] .J Mol Biol，1999，285(1)： 1-32. [9] MOMANY C，KOVARI L C，PRONGAY A J，et al. Crystal structure of dimeric HIV-1 capsid protein[J] .Nat Struct Biol，1996，3(9)： 763-770. [10] TANG S，MURAKAMI T，AGRESTA B E，et al. Human immunodeficiency virus type 1 N-terminal capsid mutants that exhibit aberrant core morphology and are blocked in initiation of reverse transcription in infected cells[J] . J Virol，2001，75(19)： 9357-9366. [11] TOWERS G J，HATZIIOANNOU T，COWAN S，et al. Cyclophilin A modulates the sensitivity of HIV-1 to host restriction factors[J] . Nat Med，2003，9(9)： 1138-1143. [12] LI S，HILL C P，SUNDQUIST W I，et al. Image reconstructions of helical assemblies of the HIV-1 CA protein[J] . Nature，2000，407(6802)： 409-413. [13] FORSHEY B M，VON SCHWEDLER U，SUNDQUIST W I，et al.Formation of a human immunodeficienc y virus type 1 core of optimal stability is crucial for viral replication[J] .J Virol，2002，76(11)： 5667-5677. [14] TANG S，MURAKAMI T，CHENG N，et al. Human immunodeficiency virus type 1 N-terminal capsid mutants containing cores with abnormally high levels of capsid protein and virtually no reverse transcriptase[J] .J Virol，2003，77(23)： 12592-12602. [15] LI F，GOILA-GAUR R，SALZWEDEL K，et al. PA-457： a potent HIV inhibitor that disrupts core condensati on by targeting a late step in Gag processing[J] .Proc Natl Acad Sci USA，2003，100(23)： 13555-13560. [16] DE CLERCQ E. Emerging anti-HIV drugs[J] .Expert Opin Emerg Drugs，2005，10(2)：241-273. [17] TANG C，LOELIGER E，KINDE I，et al. Antiviral inhibition of the HIV-1 capsid protein[J] .J Mol Biol，2003，327(5)： 1013-1020.